feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Teva Loses Bid to Delay Paragard Lawsuit

Teva Loses Bid to Delay Paragard Lawsuit

13 Jan

•

Summary

  • A Georgia federal judge denied Teva's request to delay a Paragard trial.
  • The trial is the first of 3,800 lawsuits over the contraceptive device.
  • Teva Pharmaceuticals argued an appeal would end the litigation.
Teva Loses Bid to Delay Paragard Lawsuit

A Georgia federal judge has ruled that Teva Pharmaceuticals cannot delay the first trial in thousands of lawsuits concerning its Paragard intrauterine contraceptive device. U.S. District Judge Leigh Martin May rejected Teva's request to pause the trial, scheduled to commence on January 20, 2026. The company had sought to appeal a prior ruling that rejected its bid to have the plaintiffs' claims dismissed. Teva argued that a successful appeal would likely resolve the entire litigation, which encompasses 3,800 lawsuits filed in federal court.

Plaintiffs, however, opposed the delay, viewing it as a strategic maneuver to stall proceedings. The consolidated federal lawsuits are being overseen by Judge May, with the case of Pauline Rickard selected as the initial bellwether trial. Bellwether trials are crucial for assessing claims before juries and establishing their potential settlement value. The lawsuits allege that Teva failed to adequately warn women about the risk of the Paragard IUD breaking apart during removal, leading to injuries and fertility impacts.

Rickard's lawsuit, filed in 2021, claims she required multiple procedures for the removal of her Paragard IUD. Her case is the first of three planned bellwether trials. Teva sold Paragard to CooperSurgical in 2017, and claims against CooperSurgical have been dismissed. Teva faces claims from individuals who received the IUD while it owned the product. Judge May's decision to proceed with the trial underscores the immediate need for these cases to be heard.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
No, a Georgia federal judge has denied Teva Pharmaceuticals' request to delay the first bellwether trial concerning its Paragard IUD.
Lawsuits against Teva claim the Paragard IUD can break apart during removal, causing injuries and impacting fertility, and that the company failed to warn users.
There are currently 3,800 lawsuits consolidated in federal court against Teva Pharmaceuticals regarding its Paragard IUD device.

Read more news on

Healthside-arrow
trending

Delhi temperature drops amid cold

trending

Juventus beats Cremonese 5-0

trending

Smriti Mandhana leads RCB team

trending

JKBOSE 12th Exam Schedule

trending

Tata Punch facelift features revealed

trending

Celebrities star in more ads

trending

Paris FC knocks out PSG

trending

Alvaro Arbeloa new Real Madrid coach

trending

Richa Ghosh sledges Alyssa Healy

You may also like

Millions of Australians May Soon Access Subsidized Wegovy

20 hours ago • 5 reads

article image

AbbVie Eyes Revolution Medicines in Cancer Deal

8 Jan • 38 reads

article image

Teva Stock Soars 45%, But Are Better Buys Lurking?

15 Dec, 2025 • 151 reads

article image

Holiday Hazards: Food, Jabs, and Fairy Lights!

2 Dec, 2025 • 190 reads

article image

J&J's AAA Rating: A Dividend King's Stability

28 Nov, 2025 • 204 reads

article image